Sigma Healthcare

SIG.ASX

Health Care

Sigma Healthcare is one of the largest pharmacy franchisors in Australia with the largest footprint of branded pharmacies, lead by Chemist Warehouse, Amcal and Discount Drug Stores. Sigma has an expanding international pharmacy business with Chemist Wareh

Market Data

Price

$2.930

-0.0%
Market Cap

$33.9B

P/E Ratio

-100000.0x

EPS

$-99999.990

Div. Yield

1.12%

52-Week Change

+0.0%

Latest Earnings

Sigma Half Year Results ASX Release

26 February 2026

Revenue
$5,500
+14.9% YoY
NPAT
$392.00
+19.2% YoY
Dividend
$0.02

Sigma Healthcare delivered strong first half results with normalised EBIT up 18.7% to $582.9M and revenue growth of 14.9% to $5.5B, driven by Australian Chemist Warehouse store sales growth of 17.2% and accelerating international expansion. The company is on track to deliver $100M annual synergies by FY29 and maintains a conservative balance sheet with net debt down to $635.1M. Key points: Strong double-digit growth with normalised EBIT up 18.7% and revenue up 14.9%; Australian Chemist Warehouse stores delivered 17.2% sales growth with 15.0% like-for-like growth; International expansion accelerating with retail network sales up 24.5% and 11.1% like-for-like growth

Recent Announcements

26 Feb 2026 Supplementary Positive

Sigma Half Year Results Presentation

Sigma Healthcare Limited reported strong 1H26 results with normalised revenue up 14.9% to $5.5bn and normalised EBIT up 18.7% to $582.9m, driven by growth across its domestic pharmacy network (550 Chemist Warehouse branded stores, up 13), international expansion (97 stores, up 12), and $13m in merger synergies achieved on track toward a $100m target by FY29.

26 Feb 2026 Actual Results Positive

Sigma Half Year Results ASX Release

Sigma Healthcare delivered strong first half results with normalised EBIT up 18.7% to $582.9M and revenue growth of 14.9% to $5.5B, driven by Australian Chemist Warehouse store sales growth of 17.2% and accelerating international expansion. The company is on track to deliver $100M annual synergies by FY29 and maintains a conservative balance sheet with net debt down to $635.1M. Key points: Strong double-digit growth with normalised EBIT up 18.7% and revenue up 14.9%; Australian Chemist Warehouse stores delivered 17.2% sales growth with 15.0% like-for-like growth; International expansion accelerating with retail network sales up 24.5% and 11.1% like-for-like growth

19 Feb 2026 Actual Results Neutral

FY26 Half Year Results Information

This is an announcement about Sigma Healthcare's upcoming FY26 half-year results release on February 26, 2026, not actual results. The announcement provides comparative pro-forma data showing the merged entity (following Chemist Warehouse acquisition) generated revenue of $4.8B and normalized NPAT of $329M in 1H25 pro-forma. The actual financial statements included show statutory results with revenue of $2.0B and NPAT of $310M. Key points: Successful completion of Chemist Warehouse Group acquisition creating merged healthcare giant; Pro-forma normalized NPAT of $329M demonstrates strong earning power of combined entity; Strong operating cash flow generation of $429M in the half year

13 Jan 2026 Date Announcement Neutral

FY26 Half Year Results announcement date

Sigma Healthcare Limited will announce its FY26 half-year results for the period ending 31 December 2025 on Thursday 26 February 2026, followed by a webcast presentation at 10:00am AEDT.

Get real-time alerts for SIG

Receive AI-powered earnings summaries and instant notifications when Sigma Healthcare releases results.

Register Free